Drugs.com - Clinical Trials

Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology

SPRING HOUSE, Pa., (January 23, 2025) – Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad...

Feb 9, 2025 - 21:44
 0
Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living with Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology
SPRING HOUSE, Pa., (January 23, 2025) – Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad...
Read More

Tags:

Previous Article

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycreti...

Next Article

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC...

Related Posts

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025  0

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Receives FDA Fast Track Designation ...

Feb 9, 2025  0

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Trac...

Feb 9, 2025  0